Fusion Antibodies PLC Launch of Rational Affinity Maturation Platform (5855K)
December 17 2018 - 2:00AM
UK Regulatory
TIDMFAB
RNS Number : 5855K
Fusion Antibodies PLC
17 December 2018
17 December 2018
Fusion Antibodies plc
("Fusion" or the "Company")
Launch of new Rational Affinity Maturation Platform (RAMP(TM)
)
Fusion Antibodies plc (AIM: FAB), a pharmaceutical contract
research organisation specialising in antibody engineering
services, announces that its new Rational Affinity Maturation
Platform ("RAMP(TM) ") was launched at the Antibody Engineering
Conference in San Diego last week. At the conference, Dr Richard
Buick, Chief Technical Officer of the Company, gave a presentation
on RAMP(TM) to delegates which included discovery scientists from
the pharmaceutical and biotech industry, as well as hosting a
number of smaller events.
RAMP(TM) is Fusion's new proprietary service, designed to
improve the affinity of therapeutic antibodies being developed by
drug discovery companies. The benefits of improved affinity include
improved efficacy of the treatment and the potential for lower
dosages, which greatly reduces production costs for the
manufacturer and may improve tolerability in the patient.
Previous approaches to affinity maturation have been
predominantly focused on screening high volumes of randomly
produced mutations. Fusion's novel solution involves the rational
in silico design, improving binding and stability of a much smaller
number of variants from which RAMP(TM) enables selection of a lead
drug candidate. This greatly reduces the laboratory resources and
time required, thus accelerating the customer's drug development
programme towards clinical trials.
The Company has applied for patent protection of this novel
approach to improving efficacy of therapeutic antibodies being
developed by its customers. The funds raised by the Company in
December 2017, at the time of the Company's admission to AIM, have
been used to successfully bring this new service to fruition.
RAMP(TM) will be offered to the Company's customers on a fee for
service basis, with milestone success payments sought where
appropriate. As previously announced, the introduction of RAMP(TM)
is not expected to generate significant revenues in the financial
period ending March 2019 but is expected to contribute to the
Company's growth in the following year.
Commenting, Paul Kerr, CEO of Fusion Antibodies said: "Launching
this service was one of our goals for IPO so we're delighted it has
now been successfully introduced."
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 740 001
Paul McManus Mob: +44 (0)7980 541 983
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications. The Company's ordinary shares were admitted to
trading on AIM on 18 December 2017. Fusion provides a broad range
of services in antibody generation, development, production,
characterisation and optimisation. These services include antigen
expression, antibody production, purification and sequencing,
antibody humanisation using Fusion's proprietary CDRx(TM) platform
and the production of antibody generating stable cell lines to
provide material for use in clinical trials. Since 2012, the
Company has successfully sequenced over 250 antibodies and
successfully completed over 100 humanisation projects for its
international, blue-chip client base.
The Company was established in 2001 as a spin out from Queen's
University Belfast. It was initially a drug development business
but revised its operations to focus on CRO work in 2011. The
Company has a highly experienced management team with a combined 47
years' experience in the biopharma industry. The global monoclonal
antibody therapeutics market, which accounted for 43 per cent. of
the global biologics market in 2016, was valued at between $85.4
billion and $86.7 billion in 2015 and is forecast to increase at a
CAGR of between 8.2 per cent. and 12.2 per cent. for the period
2016 to 2024.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCLLFLRFALSLIT
(END) Dow Jones Newswires
December 17, 2018 02:00 ET (07:00 GMT)
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Fusion Antibodies (LSE:FAB)
Historical Stock Chart
From Apr 2023 to Apr 2024